Compare · MDLN vs PAVM
MDLN vs PAVM
Side-by-side comparison of Medline Inc. (MDLN) and PAVmed Inc. (PAVM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PAVM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 2479.6x PAVM ($19.4M).
- MDLN has been more active in the news (7 items in the past 4 weeks vs 1 for PAVM).
- MDLN has more recent analyst coverage (25 ratings vs 0 for PAVM).
- Company
- Medline Inc.
- PAVmed Inc.
- Price
- -
- -
- Market cap
- $48.08B
- $19.4M
- 1M return
- -
- -40.40%
- 1Y return
- -
- -84.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 0
PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest PAVM
- Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
- PAVmed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- PAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.
- SEC Form 10-Q filed by PAVmed Inc.
- Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
- Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
- Lucid Diagnostics to Participate in Upcoming Investor Conferences
- PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026